Telephone
61.3.9863.6477
Address
84 Hotham Street Corporate One Preston, Victoria (VIC) 3072
Description
Hexima Ltd. is a clinical stage, anti-infectives focused biotechnology company. It engages in the business of researching and developing plant-derived proteins for applications as human therapeutics. The company was founded by Adrienne E. Clarke, Marilyn Ann Anderson, Robyn L. Heath, and Angela Atkinson in 1998 and is headquartered in Preston, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.01 - 0.02
Trade Value (12mth)
AU$1,092.00
1 week
0%
1 month
4.55%
YTD
4.55%
1 year
35.29%
All time high
0.5
EPS 3 yr Growth
-58.600%
EBITDA Margin
N/A
Operating Cashflow
-$2m
Free Cash Flow Return
-48.00%
ROIC
-52.20%
Interest Coverage
N/A
Quick Ratio
16.90
Shares on Issue (Fully Dilluted)
167m
HALO Sector
Healthcare
Next Company Report Date
28-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
31 October 23 |
Quarterly Activities Report and Appendix 4C - Sep-23 Qtr
×
Quarterly Activities Report and Appendix 4C - Sep-23 Qtr |
31 October 22 |
Quarterly Activities Report and Appendix 4C - Sep-22 Qtr
×
Quarterly Activities Report and Appendix 4C - Sep-22 Qtr |
31 January 23 |
Results of Meeting
×
Results of Meeting |
31 January 22 |
Quarterly Activities Report and Appendix 4C
×
Quarterly Activities Report and Appendix 4C |
31 August 23 |
Appendix 4E
×
Appendix 4E |
31 August 23 |
2023 Annual Report
×
2023 Annual Report |
31 August 23 |
Appendix 4G and Corporate Governance Statement
×
Appendix 4G and Corporate Governance Statement |
30 September 22 |
Annual Report 2022
×
Annual Report 2022 |
30 September 22 |
Appendix 4G and Corporate Governance Statement
×
Appendix 4G and Corporate Governance Statement |
30 September 22 |
2022 Annual General Meeting Date
×
2022 Annual General Meeting Date |
30 November 22 |
Change in substantial holding
×
Change in substantial holding |
30 June 21 |
Media Interview and Investor Presentation
×
Media Interview and Investor Presentation |
30 August 22 |
Appendix 4E & Preliminary Final Report
×
Appendix 4E & Preliminary Final Report |
30 August 22 |
Shareholder Update
×
Shareholder Update |
29 July 21 |
APMA presentation and investor webinar
×
APMA presentation and investor webinar |
29 April 22 |
ShareCafe Presentation
×
ShareCafe Presentation |
29 April 22 |
Quarterly Activities Report and Appendix 4C
×
Quarterly Activities Report and Appendix 4C |
28 March 22 |
Pezadeftide Mode of Action Presentation Released
×
Pezadeftide Mode of Action Presentation Released |
28 July 23 |
Quarterly Activities Report and Appendix 4C - Jun-2023
×
Quarterly Activities Report and Appendix 4C - Jun-2023 |
28 February 23 |
Appendix 4D and Interim Financial Report
×
Appendix 4D and Interim Financial Report |
28 February 22 |
Change of Director's Interest Notice - Dr van der Weerden
×
Change of Director's Interest Notice - Dr van der Weerden |
28 April 22 |
Notification regarding unquoted securities - HXL
×
Notification regarding unquoted securities - HXL |
27 September 22 |
Change in substantial holding
×
Change in substantial holding |
27 September 21 |
Presenting at Switzer Small & Micro-Cap Virtual Investor Day
×
Presenting at Switzer Small & Micro-Cap Virtual Investor Day |
27 October 23 |
Notice of Annual General Meeting and Proxy Form
×
Notice of Annual General Meeting and Proxy Form |
27 October 23 |
Virtual Meeting Online Guide
×
Virtual Meeting Online Guide |
27 January 23 |
Quarterly Activities Report and Appendix 4C - Dec-22 Qtr
×
Quarterly Activities Report and Appendix 4C - Dec-22 Qtr |
27 August 21 |
Annual Report 2021
×
Annual Report 2021 |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.